4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Pulmonary Hypertension by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 885 ongoing clinical trials involving Pulmonary Hypertension
Of the 885 trials,420 trials are in Phase III
Furthermore, 230 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Pulmonary Hypertension by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Pulmonary Hypertension, a cardiovascular indication. The largest number of ongoing clinical trials for Pulmonary Hypertension is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Pulmonary Hypertension-related drug trials.

Actelion Pharmaceuticals Ltd: The leading ongoing Pulmonary Hypertension related clinical trial sponsor

Actelion Pharmaceuticals Ltd is the top sponsor for Pulmonary Hypertension-related ongoing clinical trials.

United Therapeutics Corp, Bayer AG, and Acceleron Pharma Inc are among other notable clinical trial sponsors involved in Pulmonary Hypertension. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Pulmonary Hypertension

Macitentan (ACT-064992, Opsumit, Zependo), Selexipag (Uptravi), and Riociguat (Adempas) are among the key marketed drugs involving Pulmonary Hypertension.

Macitentan (ACT-064992, Opsumit, Zependo) is a novel dual endothelin receptor antagonist (ERA). It functions via Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Antagonist; Endothelin B Receptor (Endothelin Receptor Non Selective Type or EDNRB) Antagonist mechanism of action. It is formulated as film coated tablets for the oral route of administration. Macitentan s indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for pulmonary arterial hypertension. Macitentan was first approved in 2013 and is marketed globally including the US, the UK, France, and Australia by several giant pharma including Actelion Pharmaceuticals Ltd, and Janssen Inc.

Selexipag (Uptravi) is an antithrombotic agent. It functions via Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR) Agonist mechanism of action. It is formulated as film coated tablets for oral route of administration and powder for solution for intravenous route of administration. Uptravi is indicated for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization. Uptravi is also indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. Selexipag was first approved in 2015 and is marketed globally including the US, the UK, France, and Australia by several giant pharma including Actelion Pharmaceuticals Ltd, and Janssen-Cilag Pharma GmbH.